AlphAIAlphAI — Financial news for AI agents
investing.comNOV 41 min read$UTHR

United Therapeutics earnings missed by $0.50, revenue topped estimates

United Therapeutics (UTHR) reported Q3 EPS of $5.71, missing estimates by $0.50, but revenue of $832.5M exceeded expectations. The stock is up 11.60% in 3 months and 34.39% in 12 months. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Nov 4, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$UTHR
Bearish
high confidence
Mentioned
$UTHR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$UTHRBearishHigh
01

Why it matters

The earnings miss is likely to trigger short‑term selling pressure, though the revenue beat may cushion the decline.

02

Market read

Primary earnings disclosure for a mid‑cap biotech; material for traders.

03

What to watch

Potential pipeline developments not discussed may support longer‑term upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

United Therapeutics reported Q3 results with an EPS miss but revenue beat, accompanied by a stock close at $601.32.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

Q3 EPS $5.71 missed estimate by $0.50; revenue $832.5M beat $785.44M consensus.

Expected impact

likely downward pressure as market prices in the EPS miss

Evidence & confidence

The miss is material and the company is mid‑cap; investors typically react negatively to EPS shortfalls.

Market effects

Sector

Biotech/healthcare sector may see modest pullback as earnings miss signals slower growth.

Regional

U.S. markets may see slight dip in related biotech stocks.

Global

Limited; impact confined to UTHR and peers.

Counterpoint

What could challenge this read

The revenue beat could offset the EPS miss, offering a buying opportunity on dip.

Key entities

  • company
    United Therapeutics

    Biopharma firm listed on NASDAQ.

Read at source← All news

StoryUnited Therapeutics reports Q3 2026 earnings miss despite revenue beat

Also covered by

3 outlets

Related articles

NOV 4
$UTHRMed

United Therapeutics Q3 2026 slides: record revenue, robust pipeline

United Therapeutics (UTHR) reported Q3 2026 revenue of $833M, up 4% YoY, but missed EPS estimates, causing a 2.75% stock decline. Tyvaso franchise revenue grew 5% YoY to $504M. The company advanced its pipeline, with FDA accepting applications for Tyvaso in IPF and ralinepag in PAH, both with 2027 PDUFA dates. Operating cash flow was $1.4B, and a $2B share repurchase program was authorized.

investing.com7 min
NOV 4
$UTHRMedAI 8/10

United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.

minichart.com.sg2 min
NOV 4
$UTHRHigh

United Therapeutics buys out Pfizer royalty for $525 million

United Therapeutics (UTHR) will pay $525M to Pfizer's Arena subsidiary to end royalty obligations on ralinepag, a drug for pulmonary arterial hypertension. The FDA is reviewing an application for oral ralinepag, with a decision expected by June 24, 2027. United Therapeutics acquired rights to ralinepag in 2018 and is also developing an inhaled version. According to the company, the transaction reflects confidence in the drug's revenue potential.

investing.com1 min